eligibility_summary
Include: adults (≥18) with histologically confirmed NSCLC, stage IIIb/IIIc/IVa/IVb at diagnosis, first diagnosis between Jan 1, 2009 and latest year. Exclude: those given curative-intent radiation (>50 Gy). If data include diagnoses after 2021, exclude stage IIIb due to 2022 guideline changes that preclude distinguishing curative radiation in IIIb surgical cases.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Completed observational registry study (DELINOR, Norway) evaluating real‑world effectiveness and sequencing of metastatic NSCLC therapies (2009–2022). Drugs/types and mechanisms: small‑molecule TKIs—ALK/ROS1 inhibitors lorlatinib (3rd‑gen), crizotinib (ALK/ROS1/MET), brigatinib, ceritinib, alectinib, EGFR TKIs erlotinib, gefitinib (1st‑gen), afatinib/dacomitinib (2nd‑gen pan‑ErbB), osimertinib (3rd‑gen incl T790M), entrectinib (ROS1/NTRK/ALK). Monoclonal antibodies—atezolizumab (anti‑PD‑L1), pembrolizumab and nivolumab (anti‑PD‑1), bevacizumab (anti‑VEGF‑A anti‑angiogenic). Cytotoxics—paclitaxel/docetaxel (taxane microtubule stabilizers), carboplatin (DNA‑crosslinking platinum). Targets/pathways: tumor oncogenic kinases (ALK, ROS1, EGFR, NTRK, MET→MAPK/PI3K), immune checkpoints (PD‑1/PD‑L1 on T cells/tumor cells), angiogenesis (VEGF‑A/endothelium), microtubules and DNA in proliferating cancer cells.